Pomalidomide-Based Regimens for Treatment of Relapsed and Relapsed/Refractory Multiple Myeloma: Systematic Review and Meta-analysis of Phase 2 and 3 Clinical Trials

Adeela Mushtaq; Ahmad Iftikhar; Hamza Hassan; Midhat Lakhani; F. N.U. Sagar; Ahmad Kamal; Umar Zahid; Zeeshan Ali; Faryal Razzaq; Muhammad Abu Zar; Syeda Fatima Hassan; Ahmad Safdar; Sreejata Raychaudhuri; Faiz Anwer

doi:10.1016/j.clml.2019.04.003

Pomalidomide-Based Regimens for Treatment of Relapsed and Relapsed/Refractory Multiple Myeloma: Systematic Review and Meta-analysis of Phase 2 and 3 Clinical Trials

Adeela Mushtaq
, Ahmad Iftikhar
, Hamza Hassan
, Midhat Lakhani
, F. N.U. Sagar
, Ahmad Kamal
, Umar Zahid
, Zeeshan Ali
, Faryal Razzaq
, Muhammad Abu Zar
, Syeda Fatima Hassan
, Ahmad Safdar
, Sreejata Raychaudhuri
, Faiz Anwer

Medicine

Research output: Contribution to journal › Article › peer-review

14 Scopus citations

Abstract

We performed a meta-analysis to evaluate the efficacy outcomes of different pomalidomide (Pom) regimens in relapsed/refractory multiple myeloma (RRMM). Three-drug Pom regimens yielded double the response rates compared to Pom + low-dose dexamethasone (LoDex), and notably better outcomes than bortezomib + Pom + LoDex and carfilzomib + Pom + LoDex. Ongoing trials of Pom with various monoclonal antibodies will provide further insight into the role of pomalidomide for RRMM.

Original language	English (US)
Pages (from-to)	447-461
Number of pages	15
Journal	Clinical Lymphoma, Myeloma and Leukemia
Volume	19
Issue number	7
DOIs	https://doi.org/10.1016/j.clml.2019.04.003
State	Published - Jul 2019

Keywords

Adverse event
Immunomodulator
Outcome
Overall response
Pom-dex

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1016/j.clml.2019.04.003

Cite this

Mushtaq, A., Iftikhar, A., Hassan, H., Lakhani, M., Sagar, F. N. U., Kamal, A., Zahid, U., Ali, Z., Razzaq, F., Zar, M. A., Hassan, S. F., Safdar, A., Raychaudhuri, S., & Anwer, F. (2019). Pomalidomide-Based Regimens for Treatment of Relapsed and Relapsed/Refractory Multiple Myeloma: Systematic Review and Meta-analysis of Phase 2 and 3 Clinical Trials. Clinical Lymphoma, Myeloma and Leukemia, 19(7), 447-461. https://doi.org/10.1016/j.clml.2019.04.003

Pomalidomide-Based Regimens for Treatment of Relapsed and Relapsed/Refractory Multiple Myeloma: Systematic Review and Meta-analysis of Phase 2 and 3 Clinical Trials. / Mushtaq, Adeela; Iftikhar, Ahmad; Hassan, Hamza et al.
In: Clinical Lymphoma, Myeloma and Leukemia, Vol. 19, No. 7, 07.2019, p. 447-461.

Research output: Contribution to journal › Article › peer-review

Mushtaq, A, Iftikhar, A, Hassan, H, Lakhani, M, Sagar, FNU, Kamal, A, Zahid, U, Ali, Z, Razzaq, F, Zar, MA, Hassan, SF, Safdar, A, Raychaudhuri, S & Anwer, F 2019, 'Pomalidomide-Based Regimens for Treatment of Relapsed and Relapsed/Refractory Multiple Myeloma: Systematic Review and Meta-analysis of Phase 2 and 3 Clinical Trials', Clinical Lymphoma, Myeloma and Leukemia, vol. 19, no. 7, pp. 447-461. https://doi.org/10.1016/j.clml.2019.04.003

@article{e07a46f51fae41faad4f950f3fcceabc,

title = "Pomalidomide-Based Regimens for Treatment of Relapsed and Relapsed/Refractory Multiple Myeloma: Systematic Review and Meta-analysis of Phase 2 and 3 Clinical Trials",

abstract = "We performed a meta-analysis to evaluate the efficacy outcomes of different pomalidomide (Pom) regimens in relapsed/refractory multiple myeloma (RRMM). Three-drug Pom regimens yielded double the response rates compared to Pom + low-dose dexamethasone (LoDex), and notably better outcomes than bortezomib + Pom + LoDex and carfilzomib + Pom + LoDex. Ongoing trials of Pom with various monoclonal antibodies will provide further insight into the role of pomalidomide for RRMM.",

keywords = "Adverse event, Immunomodulator, Outcome, Overall response, Pom-dex",

author = "Adeela Mushtaq and Ahmad Iftikhar and Hamza Hassan and Midhat Lakhani and Sagar, \{F. N.U.\} and Ahmad Kamal and Umar Zahid and Zeeshan Ali and Faryal Razzaq and Zar, \{Muhammad Abu\} and Hassan, \{Syeda Fatima\} and Ahmad Safdar and Sreejata Raychaudhuri and Faiz Anwer",

note = "Publisher Copyright: {\textcopyright} 2019 Elsevier Inc.",

year = "2019",

month = jul,

doi = "10.1016/j.clml.2019.04.003",

language = "English (US)",

volume = "19",

pages = "447--461",

journal = "Clinical Lymphoma, Myeloma and Leukemia",

issn = "2152-2650",

publisher = "Cancer Media Group",

number = "7",

}

TY - JOUR

T1 - Pomalidomide-Based Regimens for Treatment of Relapsed and Relapsed/Refractory Multiple Myeloma

T2 - Systematic Review and Meta-analysis of Phase 2 and 3 Clinical Trials

AU - Mushtaq, Adeela

AU - Iftikhar, Ahmad

AU - Hassan, Hamza

AU - Lakhani, Midhat

AU - Sagar, F. N.U.

AU - Kamal, Ahmad

AU - Zahid, Umar

AU - Ali, Zeeshan

AU - Razzaq, Faryal

AU - Zar, Muhammad Abu

AU - Hassan, Syeda Fatima

AU - Safdar, Ahmad

AU - Raychaudhuri, Sreejata

AU - Anwer, Faiz

PY - 2019/7

Y1 - 2019/7

N2 - We performed a meta-analysis to evaluate the efficacy outcomes of different pomalidomide (Pom) regimens in relapsed/refractory multiple myeloma (RRMM). Three-drug Pom regimens yielded double the response rates compared to Pom + low-dose dexamethasone (LoDex), and notably better outcomes than bortezomib + Pom + LoDex and carfilzomib + Pom + LoDex. Ongoing trials of Pom with various monoclonal antibodies will provide further insight into the role of pomalidomide for RRMM.

AB - We performed a meta-analysis to evaluate the efficacy outcomes of different pomalidomide (Pom) regimens in relapsed/refractory multiple myeloma (RRMM). Three-drug Pom regimens yielded double the response rates compared to Pom + low-dose dexamethasone (LoDex), and notably better outcomes than bortezomib + Pom + LoDex and carfilzomib + Pom + LoDex. Ongoing trials of Pom with various monoclonal antibodies will provide further insight into the role of pomalidomide for RRMM.

KW - Adverse event

KW - Immunomodulator

KW - Outcome

KW - Overall response

KW - Pom-dex

UR - https://www.scopus.com/pages/publications/85064913775

UR - https://www.scopus.com/pages/publications/85064913775#tab=citedBy

U2 - 10.1016/j.clml.2019.04.003

DO - 10.1016/j.clml.2019.04.003

M3 - Article

AN - SCOPUS:85064913775

SN - 2152-2650

VL - 19

SP - 447

EP - 461

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

IS - 7

ER -

Pomalidomide-Based Regimens for Treatment of Relapsed and Relapsed/Refractory Multiple Myeloma: Systematic Review and Meta-analysis of Phase 2 and 3 Clinical Trials

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this